JP2015517458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517458A5 JP2015517458A5 JP2015509430A JP2015509430A JP2015517458A5 JP 2015517458 A5 JP2015517458 A5 JP 2015517458A5 JP 2015509430 A JP2015509430 A JP 2015509430A JP 2015509430 A JP2015509430 A JP 2015509430A JP 2015517458 A5 JP2015517458 A5 JP 2015517458A5
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- combination
- des
- human insulin
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 30
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 claims 23
- 230000002641 glycemic effect Effects 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 230000002608 insulinlike Effects 0.000 claims 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 14
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 9
- 230000009286 beneficial effect Effects 0.000 claims 7
- 102000004877 Insulin Human genes 0.000 claims 6
- 108090001061 Insulin Proteins 0.000 claims 6
- 229940125396 insulin Drugs 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 235000012054 meals Nutrition 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 125000002843 carboxylic acid group Chemical group 0.000 claims 4
- 230000037213 diet Effects 0.000 claims 4
- 235000005911 diet Nutrition 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 2
- -1 carboxyethyl Chemical group 0.000 claims 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010092217 Long-Acting Insulin Proteins 0.000 claims 1
- 102000016261 Long-Acting Insulin Human genes 0.000 claims 1
- 229940100066 Long-acting insulin Drugs 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 229940123452 Rapid-acting insulin Drugs 0.000 claims 1
- 108010026951 Short-Acting Insulin Proteins 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000004026 insulin derivative Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12166252 | 2012-05-01 | ||
| EP12166251 | 2012-05-01 | ||
| EP12166251.4 | 2012-05-01 | ||
| EP12166252.2 | 2012-05-01 | ||
| US201261641540P | 2012-05-02 | 2012-05-02 | |
| US201261641544P | 2012-05-02 | 2012-05-02 | |
| US61/641,540 | 2012-05-02 | ||
| US61/641,544 | 2012-05-02 | ||
| PCT/EP2013/059073 WO2013164375A1 (en) | 2012-05-01 | 2013-05-01 | Pharmaceutical composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517458A JP2015517458A (ja) | 2015-06-22 |
| JP2015517458A5 true JP2015517458A5 (OSRAM) | 2016-06-16 |
| JP6262206B2 JP6262206B2 (ja) | 2018-01-17 |
Family
ID=49514218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509430A Active JP6262206B2 (ja) | 2012-05-01 | 2013-05-01 | 医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9884094B2 (OSRAM) |
| EP (1) | EP2844274B1 (OSRAM) |
| JP (1) | JP6262206B2 (OSRAM) |
| AU (1) | AU2013255880B2 (OSRAM) |
| BR (1) | BR112014026442A8 (OSRAM) |
| CA (1) | CA2872083A1 (OSRAM) |
| MX (1) | MX363119B (OSRAM) |
| RU (1) | RU2670106C2 (OSRAM) |
| WO (1) | WO2013164375A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1969004E (pt) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Composições que compreendem uma insulina acilada e zinco e método para criar tais composições |
| JP6049625B2 (ja) | 2010-10-27 | 2016-12-21 | ノヴォ ノルディスク アー／エス | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 |
| EP2976096B1 (en) * | 2013-03-20 | 2019-02-27 | Novo Nordisk A/S | Insulin dosing regimen |
| US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
| WO2016001185A1 (en) * | 2014-07-02 | 2016-01-07 | Novo Nordisk A/S | Dosage regimen for the treatment of diabetes |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| CN114096269B (zh) | 2019-07-12 | 2024-06-11 | 诺和诺德股份有限公司 | 高浓度胰岛素制剂 |
| US20250154220A1 (en) * | 2023-11-15 | 2025-05-15 | Ambio, Inc. | Insulin analogs for the treatment of human metabolic disorder and disease |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| KR910700262A (ko) | 1988-12-23 | 1991-03-14 | 안네 제케르 | 사람 인슐린 유사체 |
| NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
| ATE181732T1 (de) | 1989-04-19 | 1999-07-15 | Novo Nordisk As | Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden |
| EP0792290B1 (en) | 1993-09-17 | 2001-08-29 | Novo Nordisk A/S | Acylated insulin |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| CO4970787A1 (es) * | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| WO2005012347A2 (en) | 2003-08-05 | 2005-02-10 | Novo Nordisk A/S | Novel insulin derivatives |
| EP2264066A3 (en) | 2003-08-05 | 2011-07-27 | Novo Nordisk A/S | Novel insulin derivatives |
| PT1969004E (pt) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Composições que compreendem uma insulina acilada e zinco e método para criar tais composições |
| MX2008014061A (es) | 2006-05-09 | 2008-11-14 | Novo Nordisk As | Derivado de insulina. |
| US9034818B2 (en) | 2007-06-13 | 2015-05-19 | Novo Nordisk A/S | Pharmaceutical formulations comprising an insulin derivative |
| WO2009104199A1 (en) * | 2008-02-19 | 2009-08-27 | Biocon Limited | A method of obtaining purified heterologous insulins expressed in yeast |
| ES2607003T3 (es) * | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria |
| SI2632478T1 (sl) * | 2010-10-27 | 2019-11-29 | Novo Nordisk As | Zdravljenje sladkorne bolezni z uporabo inzulinskih injekcij, ki se dajejo v različnih injicirnih intervalih |
-
2013
- 2013-05-01 EP EP13721650.3A patent/EP2844274B1/en active Active
- 2013-05-01 AU AU2013255880A patent/AU2013255880B2/en active Active
- 2013-05-01 BR BR112014026442A patent/BR112014026442A8/pt not_active Application Discontinuation
- 2013-05-01 US US14/398,018 patent/US9884094B2/en active Active
- 2013-05-01 WO PCT/EP2013/059073 patent/WO2013164375A1/en not_active Ceased
- 2013-05-01 JP JP2015509430A patent/JP6262206B2/ja active Active
- 2013-05-01 RU RU2014147674A patent/RU2670106C2/ru active
- 2013-05-01 MX MX2014013091A patent/MX363119B/es unknown
- 2013-05-01 CA CA 2872083 patent/CA2872083A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517458A5 (OSRAM) | ||
| JP5669395B2 (ja) | 新規化合物および摂食行動に対するその効果 | |
| RU2014147674A (ru) | Фармацевтическая композиция | |
| JP2016516076A5 (OSRAM) | ||
| WO2013004983A1 (en) | Novel compounds and their effects on feeding behaviour | |
| JP2009533460A (ja) | ｈＧＬＰ−１、エクセンジン−４およびその類似体の医薬組成物 | |
| JP2008534622A5 (OSRAM) | ||
| JP2017537894A (ja) | Ｇｌｐ−１ｒおよびｇｌｐ−２ｒ二重アゴニスト活性を有する組成物及びペプチド | |
| RU2013133803A (ru) | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп | |
| CA2608311A1 (en) | Glp-1 pegylated compounds | |
| JP2010031018A5 (OSRAM) | ||
| JP2014504597A (ja) | アシル化グルカゴン類似体とインスリン類似体の組合せ物 | |
| RU2006144821A (ru) | Пролонгирующие метки полипептидов, содержащие тетразольную группировку | |
| JP2015110631A5 (OSRAM) | ||
| RU2012123739A (ru) | Фармацевтическая композиция, содержащая агонист гпп-1 и метионин | |
| CN102711805A (zh) | 包含glp-1激动剂、胰岛素和甲硫氨酸的药物组合物 | |
| US20150111820A1 (en) | Novel use of insulin derivatives | |
| EP1888103B1 (en) | Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling | |
| JP2024038042A (ja) | 肥満の治療および体重管理のためのｇｌｐ－１組成物 | |
| JP2014500244A5 (OSRAM) | ||
| Verge et al. | Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes | |
| RU2012126101A (ru) | Полипептидный конъюгат | |
| JP2013511287A5 (OSRAM) | ||
| Mikhail | Is exenatide a useful addition to diabetes therapy? | |
| Kanaujia et al. | BEYOND BORDERS: TIRZEPATIDE UNVEILED-A COMPREHENSIVE REVIEW OF DUAL TARGETING THERAPIES IN DIABETES AND OBESITY MANAGEMENT. |